<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422187</url>
  </required_header>
  <id_info>
    <org_study_id>PB-06-007</org_study_id>
    <nct_id>NCT01422187</nct_id>
  </id_info>
  <brief_title>A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease</brief_title>
  <official_title>A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center trial to further extend the assessment of the safety and efficacy of
      taliglucerase alfa in adult subjects (â‰¥18 years old) with Gaucher disease who have enrolled
      in Protocol PB-06-003. Subjects will continue to receive an intravenous (IV) infusion of
      taliglucerase alfa every two weeks. The duration of treatment will be a maximum of 21 months
      or until taliglucerase alfa is commercially available to the subject at the discretion of the
      Sponsor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spleen Volume</measure>
    <time_frame>60 months</time_frame>
    <description>Spleen volume measured by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver Volume</measure>
    <time_frame>60 months</time_frame>
    <description>Liver volume by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count</measure>
    <time_frame>60 months</time_frame>
    <description>Platelet count measure annually</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>60 months</time_frame>
    <description>Hemoglobin measure yearly</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Taliglucerase alfa 30 units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to receive 30 units/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taliglucerase alfa 60 units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to 60 units/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taliglucerase alfa</intervention_name>
    <description>Taliglucerase infusion every two weeks for 21 months</description>
    <arm_group_label>Taliglucerase alfa 30 units/kg</arm_group_label>
    <arm_group_label>Taliglucerase alfa 60 units/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully completed Protocol PB-06-001 and enrolled in Protocol PB-06-003

          -  The subject signs an informed consent

        Exclusion Criteria:

          -  Currently taking another investigational drug for any condition.

          -  Presence of any medical, emotional, behavioral or psychological condition that in the
             judgment of the Investigator would interfere with the subject's compliance with the
             requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Almon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix Ltd</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2011</study_first_submitted>
  <study_first_submitted_qc>August 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <results_first_submitted>November 6, 2015</results_first_submitted>
  <results_first_submitted_qc>November 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2015</results_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>enzyme replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Taliglucerase Alfa 30 Units/kg</title>
          <description>Subjects randomized to receive 30 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
        <group group_id="P2">
          <title>Taliglucerase Alfa 60 Units/kg</title>
          <description>Subjects randomized to 60 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
        <group group_id="P3">
          <title>Dose Adjusted</title>
          <description>Subjects randomized to 30 units/kg but with dose increased
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Personal reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Taliglucerase Alfa 30 Units/kg</title>
          <description>Subjects randomized to receive 30 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
        <group group_id="B2">
          <title>Taliglucerase Alfa 60 Units/kg</title>
          <description>Subjects randomized to 60 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
        <group group_id="B3">
          <title>Dose Adjusted</title>
          <description>Subjects randomized to 30 units/kg but with dose increased
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="13.4"/>
                    <measurement group_id="B2" value="39.9" spread="12.0"/>
                    <measurement group_id="B3" value="38.5" spread="0.7"/>
                    <measurement group_id="B4" value="41.8" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Spleen Volume</title>
        <description>Spleen volume measured by MRI</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Taliglucerase Alfa 30 Units/kg</title>
            <description>Subjects randomized to receive 30 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O2">
            <title>Taliglucerase Alfa 60 Units/kg</title>
            <description>Subjects randomized to 60 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O3">
            <title>Dose Adjusted</title>
            <description>Subjects randomized to 30 units/kg but with dose increased
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
        </group_list>
        <measure>
          <title>Spleen Volume</title>
          <description>Spleen volume measured by MRI</description>
          <units>Milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2032.0" spread="454.9"/>
                    <measurement group_id="O2" value="1960.0" spread="451.7"/>
                    <measurement group_id="O3" value="2321.7" spread="679.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1522.6" spread="429.6"/>
                    <measurement group_id="O2" value="1063.7" spread="280.7"/>
                    <measurement group_id="O3" value="1677.9" spread="609.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1193.0" spread="320.2"/>
                    <measurement group_id="O2" value="744.9" spread="130.6"/>
                    <measurement group_id="O3" value="1536.3" spread="506.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068.7" spread="264.6"/>
                    <measurement group_id="O2" value="634.0" spread="71.0"/>
                    <measurement group_id="O3" value="1256.6" spread="385.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1137.4" spread="314.6"/>
                    <measurement group_id="O2" value="526.8" spread="48.5"/>
                    <measurement group_id="O3" value="1070.0" spread="280.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1019.2" spread="285.3"/>
                    <measurement group_id="O2" value="516.1" spread="54.5"/>
                    <measurement group_id="O3" value="919.9" spread="180.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Volume</title>
        <description>Liver volume by MRI</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Taliglucerase Alfa 30 Units/kg</title>
            <description>Subjects randomized to receive 30 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O2">
            <title>Taliglucerase Alfa 60 Units/kg</title>
            <description>Subjects randomized to 60 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O3">
            <title>Dose Adjusted</title>
            <description>Subjects randomized to 30 units/kg but with dose increased
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Volume</title>
          <description>Liver volume by MRI</description>
          <units>Milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3103.4" spread="324.7"/>
                    <measurement group_id="O2" value="2536.1" spread="170.0"/>
                    <measurement group_id="O3" value="2488.6" spread="206.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2619.3" spread="266.4"/>
                    <measurement group_id="O2" value="2155.2" spread="104.8"/>
                    <measurement group_id="O3" value="2048.0" spread="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2367.9" spread="212.8"/>
                    <measurement group_id="O2" value="1939.5" spread="101.5"/>
                    <measurement group_id="O3" value="2064.0" spread="202.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2429.6" spread="229.6"/>
                    <measurement group_id="O2" value="2010.6" spread="143.5"/>
                    <measurement group_id="O3" value="1959.0" spread="140.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2429.1" spread="283.2"/>
                    <measurement group_id="O2" value="1971.2" spread="179.3"/>
                    <measurement group_id="O3" value="1792.2" spread="143.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2290.9" spread="233.6"/>
                    <measurement group_id="O2" value="2067.7" spread="188.9"/>
                    <measurement group_id="O3" value="1820.8" spread="196.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Count</title>
        <description>Platelet count measure annually</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Taliglucerase Alfa 30 Units/kg</title>
            <description>Subjects randomized to receive 30 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O2">
            <title>Taliglucerase Alfa 60 Units/kg</title>
            <description>Subjects randomized to 60 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O3">
            <title>Dose Adjusted</title>
            <description>Subjects randomized to 30 units/kg but with dose increased
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Count</title>
          <description>Platelet count measure annually</description>
          <units>platelets/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70975" spread="8700.6"/>
                    <measurement group_id="O2" value="70067" spread="7695.5"/>
                    <measurement group_id="O3" value="69500" spread="42500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86613" spread="11894"/>
                    <measurement group_id="O2" value="137556" spread="18358"/>
                    <measurement group_id="O3" value="88000" spread="65000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103250" spread="17008"/>
                    <measurement group_id="O2" value="168778" spread="23717"/>
                    <measurement group_id="O3" value="101000" spread="68000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106775" spread="13517"/>
                    <measurement group_id="O2" value="155667" spread="16060"/>
                    <measurement group_id="O3" value="94500" spread="64500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100643" spread="15314"/>
                    <measurement group_id="O2" value="184000" spread="16688"/>
                    <measurement group_id="O3" value="103000" spread="53000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104986" spread="18961"/>
                    <measurement group_id="O2" value="180625" spread="17062"/>
                    <measurement group_id="O3" value="103500" spread="60500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin</title>
        <description>Hemoglobin measure yearly</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Taliglucerase Alfa 30 Units/kg</title>
            <description>Subjects randomized to receive 30 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O2">
            <title>Taliglucerase Alfa 60 Units/kg</title>
            <description>Subjects randomized to 60 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
          <group group_id="O3">
            <title>Dose Adjusted</title>
            <description>Subjects randomized to 30 units/kg but with dose increased
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <description>Hemoglobin measure yearly</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="0.7"/>
                    <measurement group_id="O2" value="11.6" spread="0.9"/>
                    <measurement group_id="O3" value="12.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="0.7"/>
                    <measurement group_id="O2" value="14.2" spread="0.7"/>
                    <measurement group_id="O3" value="14.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="0.8"/>
                    <measurement group_id="O2" value="14.1" spread="0.7"/>
                    <measurement group_id="O3" value="14.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="0.5"/>
                    <measurement group_id="O2" value="14.2" spread="0.8"/>
                    <measurement group_id="O3" value="14.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="0.6"/>
                    <measurement group_id="O2" value="14.0" spread="0.8"/>
                    <measurement group_id="O3" value="14.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="0.9"/>
                    <measurement group_id="O2" value="13.9" spread="0.6"/>
                    <measurement group_id="O3" value="14.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Taliglucerase Alfa 30 Units/kg</title>
          <description>Subjects randomized to receive 30 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
        <group group_id="E2">
          <title>Taliglucerase Alfa 60 Units/kg</title>
          <description>Subjects randomized to 60 units/kg
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
        <group group_id="E3">
          <title>Dose Adjusted</title>
          <description>Subjects randomized to 30 units/kg but with dose increased
Taliglucerase alfa: Taliglucerase infusion every two weeks for 21 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid Carcinoma</sub_title>
                <description>papillary thyroid carcinoma that required total thyroidectomy and left node resection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>right hip arthrosis which required artificial hip implantation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glen Park</name_or_title>
      <organization>Target Health Inc.</organization>
      <phone>212-681-2100</phone>
      <email>gpark@targethealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

